Cargando…
Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign
OBJECTIVES: The outbreak of the 2019 coronavirus disease (COVID-19) pandemic in Wuhan, China, has subsided after being hard hit by the disease and subsequent city lockdown. Information on the number of people involved in Wuhan is still inadequate. This study aimed to describe the screening results o...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539137/ https://www.ncbi.nlm.nih.gov/pubmed/33035672 http://dx.doi.org/10.1016/j.cmi.2020.09.044 |
_version_ | 1783591003017445376 |
---|---|
author | Pan, Yunbao Li, Xinran Yang, Gui Fan, Junli Tang, Yueting Hong, Xiaoyue Guo, Shuang Li, Jin Yao, Dongai Cheng, Zhenshun Yuan, Yufeng Li, Yirong Wang, Xinghuan |
author_facet | Pan, Yunbao Li, Xinran Yang, Gui Fan, Junli Tang, Yueting Hong, Xiaoyue Guo, Shuang Li, Jin Yao, Dongai Cheng, Zhenshun Yuan, Yufeng Li, Yirong Wang, Xinghuan |
author_sort | Pan, Yunbao |
collection | PubMed |
description | OBJECTIVES: The outbreak of the 2019 coronavirus disease (COVID-19) pandemic in Wuhan, China, has subsided after being hard hit by the disease and subsequent city lockdown. Information on the number of people involved in Wuhan is still inadequate. This study aimed to describe the screening results of 61 437 community members in Wuchang District, Wuhan. METHODS: In mid-May 2020, Wuhan launched a population-scale city-wide SARS-CoV-2 testing campaign, which aimed to perform nucleic acid and viral antibody testing for citizens in Wuhan. Here we show the screening results of cluster sampling of 61 437 residents in Wuchang District, Wuhan, China. RESULTS: A total of 1470 (2.39%, 95% CI 2.27–2.52) individuals were detected positive for at least one antiviral antibody. Among the positive individuals, 324 (0.53%, 95% CI 0.47–0.59) and 1200 (1.95%, 95% CI 1.85–2.07) were positive for immunoglobulin IgM and IgG, respectively, and 54 (0.08%, 95% CI 0.07–0.12) were positive for both antibodies. The positive rate of female carriers of antibodies was higher than those of male counterparts (male-to-female ratio of 0.75), especially in elderly citizens (ratio of 0.18 in 90+ age subgroup), indicating a sexual discrepancy in seroprevalence. In addition, viral nucleic acid detection using real-time PCR had showed 8 (0.013%, 95% CI 0.006–0.026) asymptomatic virus carriers. DISCUSSION: The seroprevalence of SARS-CoV-2 in Wuhan was low. Most Wuhan residents are still susceptible to this virus. Precautions, such as wearing mask, frequent hand hygiene and proper social distance, are necessary before an effective vaccine or antiviral treatments are available. |
format | Online Article Text |
id | pubmed-7539137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75391372020-10-07 Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign Pan, Yunbao Li, Xinran Yang, Gui Fan, Junli Tang, Yueting Hong, Xiaoyue Guo, Shuang Li, Jin Yao, Dongai Cheng, Zhenshun Yuan, Yufeng Li, Yirong Wang, Xinghuan Clin Microbiol Infect Original Article OBJECTIVES: The outbreak of the 2019 coronavirus disease (COVID-19) pandemic in Wuhan, China, has subsided after being hard hit by the disease and subsequent city lockdown. Information on the number of people involved in Wuhan is still inadequate. This study aimed to describe the screening results of 61 437 community members in Wuchang District, Wuhan. METHODS: In mid-May 2020, Wuhan launched a population-scale city-wide SARS-CoV-2 testing campaign, which aimed to perform nucleic acid and viral antibody testing for citizens in Wuhan. Here we show the screening results of cluster sampling of 61 437 residents in Wuchang District, Wuhan, China. RESULTS: A total of 1470 (2.39%, 95% CI 2.27–2.52) individuals were detected positive for at least one antiviral antibody. Among the positive individuals, 324 (0.53%, 95% CI 0.47–0.59) and 1200 (1.95%, 95% CI 1.85–2.07) were positive for immunoglobulin IgM and IgG, respectively, and 54 (0.08%, 95% CI 0.07–0.12) were positive for both antibodies. The positive rate of female carriers of antibodies was higher than those of male counterparts (male-to-female ratio of 0.75), especially in elderly citizens (ratio of 0.18 in 90+ age subgroup), indicating a sexual discrepancy in seroprevalence. In addition, viral nucleic acid detection using real-time PCR had showed 8 (0.013%, 95% CI 0.006–0.026) asymptomatic virus carriers. DISCUSSION: The seroprevalence of SARS-CoV-2 in Wuhan was low. Most Wuhan residents are still susceptible to this virus. Precautions, such as wearing mask, frequent hand hygiene and proper social distance, are necessary before an effective vaccine or antiviral treatments are available. European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021-02 2020-10-07 /pmc/articles/PMC7539137/ /pubmed/33035672 http://dx.doi.org/10.1016/j.cmi.2020.09.044 Text en © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Pan, Yunbao Li, Xinran Yang, Gui Fan, Junli Tang, Yueting Hong, Xiaoyue Guo, Shuang Li, Jin Yao, Dongai Cheng, Zhenshun Yuan, Yufeng Li, Yirong Wang, Xinghuan Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign |
title | Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign |
title_full | Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign |
title_fullStr | Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign |
title_full_unstemmed | Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign |
title_short | Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign |
title_sort | seroprevalence of sars-cov-2 immunoglobulin antibodies in wuhan, china: part of the city-wide massive testing campaign |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539137/ https://www.ncbi.nlm.nih.gov/pubmed/33035672 http://dx.doi.org/10.1016/j.cmi.2020.09.044 |
work_keys_str_mv | AT panyunbao seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT lixinran seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT yanggui seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT fanjunli seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT tangyueting seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT hongxiaoyue seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT guoshuang seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT lijin seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT yaodongai seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT chengzhenshun seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT yuanyufeng seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT liyirong seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign AT wangxinghuan seroprevalenceofsarscov2immunoglobulinantibodiesinwuhanchinapartofthecitywidemassivetestingcampaign |